EIF3A and ovarian carcinoma: As shown in our previous study, eIF3a increases the sensitivity of ovarian cancer and non-small cell lung cancer to platinum-based chemotherapy, and the patients with a high level of eIF3a have a better prognosis (Yin et al., 2011b; Zhang Y. et al., 2015).